Trajectories of P2Y12 inhibitor adherence in patients with acute coronary syndromes
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.5704 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Jungyeon Moon und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Western University of Health Sciences, Pomona, California, USA. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Atrial Fibrillation, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Purpose
P2Y12 inhibitors (P2Y12i) reduce cardiac events after acute coronary syndromes (ACS). However, suboptimal P2Y12i adherence persists. We aimed to examine P2Y12i non‐adherence using group‐based trajectory methods and to identify adherence predictors.
Methods
We conducted a population‐based, retrospective cohort study using administrative data in Ontario, Canada of patients ≥65 years admitted for ACS between April 2014 and March 2018 with a P2Y12i dispensed within 7 days of discharge. We used group‐based trajectory models to characterize longitudinal 1‐year adherence patterns. Predictors associated with each adherence trajectory were identified by multinomial logistic regression.
Results
We included 11 917 patients using clopidogrel and 9763 using ticagrelor, aged [mean ± SD]: 77.33 ± 8.31/73.59 ± 6.79 years; men: 56.2%/65.4%, respectively. We identified 3 longitudinal adherence trajectories, that differed by agent: 75% of clopidogrel and 68% of ticagrelor patients showed a consistently adherent trajectory, while 13%/17% were gradually, and 12%/15% were rapidly non‐adherent, respectively ( p < 0.001). Differing baseline characteristics in each cohort were associated with observed adherence trajectories. Concomitant atrial fibrillation and prior bleeding history were associated with non‐adherence among clopidogrel users. Among ticagrelor users, women and older persons were more likely to be rapidly non‐adherent, adherence declining steeply starting 1 month post‐ACS.
Conclusions
We identified distinct adherence trajectories for clopidogrel and ticagrelor post‐ACS, with 3 out of 4 clopidogrel patients but only 2 out of 3 ticagrelor patients in the consistently adherent trajectory. Intensive interventions targeted to the period of steep adherence decline post‐ACS, particularly for women and older persons initiating ticagrelor, and patients with atrial fibrillation on clopidogrel should be considered and investigated further.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Western University of Health Sciences, Pomona, California, USA.
- School of Pharmacy & Pharmaceutical Sciences, University of California Irvine, Irvine, California, USA.
- ICES, Toronto, Canada.
- University of Toronto, Toronto, Ontario, Canada.
- Schulich Heart Centre Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
- Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA.
ORCID-Profile: Jungyeon Moon, Aya F Ozaki, Cynthia A Jackevicius
Förderung
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Moon, J., Ozaki, A. F., Chong, A., Sud, M., Fang, J., Austin, P. C., Ko, D. T., & Jackevicius, C. A. (2024). Trajectories of P2Y12 inhibitor adherence in patients with acute coronary syndromes. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5704
Vancouver
Moon J, Ozaki AF, Chong A, Sud M, Fang J, Austin PC, et al. Trajectories of P2Y12 inhibitor adherence in patients with acute coronary syndromes. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5704
BibTeX
@article{Moon2024,
author = {Moon, Jungyeon and Ozaki, Aya F and Chong, Alice and Sud, Maneesh and Fang, Jiming and Austin, Peter C and Ko, Dennis T and Jackevicius, Cynthia A},
title = {Trajectories of P2Y12 inhibitor adherence in patients with acute coronary syndromes},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.5704}
}
EUVIMED